Delving into the Latest Updates on Lohocla Research Corp. with Synapse

Overview

Basic Info

Introduction

Lohocla is a pioneering research and development firm that specializes in creating innovative medications for chronic pain, addiction, and various neurological and mental health disorders. The company is committed to advancing personalized medicine by developing biological markers that assist physicians in accurately prescribing their medications to the right patients. Lohocla is dedicated to staying at the cutting edge of discovery bioscience and making significant contributions to the field.

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	2
Biological products	1

Top 5 Target	Count

NMDA receptor x Nav1.7 x Nav1.8 x δ opioid receptor	1

The goal of this clinical trial is to determine the safety, tolerability and effects of Nezavist in healthy adults. The main questions it aims to answer are:
* What is the safety and maximum tolerated dose (MTD) of orally administered Nezavist formulated as a spray dried dispersion (SDD) in healthy volunteers?
* What are the pharmacokinetics (PK) of orally administered Nezavist SDD and its major metabolite (DCUKA) across a range of doses in healthy volunteers?
Researchers will compare the active drug (Nezavist) and a placebo (an inactive substance that looks like the drug) to see if there is any differences between the two groups to make sure Nezavist is safe to use in future studies for reducing alcohol consumption by individuals that have alcohol use disorder (AUD).

Start Date01 Jan 2025

Sponsor / Collaborator

Lohocla Research Corp.

[+1]

NCT06243835 / RecruitingPhase 1

A Phase 1a Randomized, Double-blind, Placebo-controlled, Single Site, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Kindolor Tosylate in Healthy Adults

The goal of this study is to test Kindolor in healthy adults. The main questions it aims to answer are:
* What is the safe dose of Kindolor in healthy volunteers?
* How is Kindolor metabolized by the human body?
Participants will undergo medical tests before and after receiving Kindolor or a placebo to see if there is any difference between the groups.

Start Date21 Apr 2024

Sponsor / Collaborator

Lohocla Research Corp.

[+1]

100 Clinical Results associated with Lohocla Research Corp.

Login to view more data

0 Patents (Medical) associated with Lohocla Research Corp.

Login to view more data

7

Literatures (Medical) associated with Lohocla Research Corp.

01 Jan 2020·Journal of Psychiatry and Brain Science

Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain

Article

Author: Hoffman, Paula L ; Tabakoff, Boris

We report on the ongoing project "A Novel Therapeutic to Ameliorate Chronic Pain and Reduce Opiate Use." Over 100 million adults in the U.S. suffer from intermittent or constant chronic pain, and chronic pain affects at least 10% of the world's population. The primary pharmaceuticals for treatment of chronic pain have been natural or synthetic opioids and the use of opioids for pain treatment has resulted in what has been called an "epidemic" of opioid abuse, addiction and lethal overdoses. We have, through a process of rational drug design, generated a novel chemical entity (NCE) and have given it the name Kindolor. Kindolor is a non-opiate, non-addicting molecule that was developed specifically to simultaneously control the aberrant activity of three targets on the peripheral sensory system that are integral in the development and propagation of chronic pain. In our initial preclinical studies, we demonstrated the efficacy of Kindolor to reduce or eliminate chronic pain in five animal models. The overall goal of the project is to complete the investigational new drug (IND)-enabling preclinical studies of Kindolor, and once IND approval is gained, we will proceed to the clinical Phase Ia and 1b safety studies and a Phase 2a efficacy study. The work is in its second year, and the present report describes progress toward our overall goal of bringing our compound to a full Phase 2 ready stage.

01 Aug 2016·European Journal of PharmacologyQ3 · MEDICINE

A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain

Q3 · MEDICINE

Article

Author: Snell, Lawrence D ; Levinson, Rock ; Rush, Anthony M ; Ren, Wenhua ; Honse, Yumiko ; Gustafson, Daniel L ; Lovinger, David ; Smothers, C Thetford ; Woodward, John J ; Matheson, Christopher J ; Wang, Ze-Jun ; Sather, William A ; Vanderlinden, Lauren ; Hoffman, Paula L ; Tabakoff, Boris

Recent understanding of the systems that mediate complex disease states, has generated a search for molecules that simultaneously modulate more than one component of a pathologic pathway. Chronic pain syndromes are etiologically connected to functional changes (sensitization) in both peripheral sensory neurons and in the central nervous system (CNS). These functional changes involve modifications of a significant number of components of signal generating, signal transducing and signal propagating pathways. Our analysis of disease-related changes which take place in sensory neurons during sensitization led to the design of a molecule that would simultaneously inhibit peripheral NMDA receptors and voltage sensitive sodium channels. In the current report, we detail the selectivity of N,N-(diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (DCUKA) for action at NMDA receptors composed of different subunit combinations and voltage sensitive sodium channels having different α subunits. We show that DCUKA is restricted to the periphery after oral administration, and that circulating blood levels are compatible with its necessary concentrations for effects at the peripheral cognate receptors/channels that were assayed in vitro. Our results demonstrate that DCUKA, at concentrations circulating in the blood after oral administration, can modulate systems which are upregulated during peripheral sensitization, and are important for generating and conducting pain information to the CNS. Furthermore, we demonstrate that DCUKA ameliorates the hyperalgesia of chronic pain without affecting normal pain responses in neuropathic and inflammation-induced chronic pain models.

05 May 2015·Oxford Handbooks Online

Biological Markers of Substance Use

Author: Boris Tabakoff ; Laszlo Takacs ; Lawrence D. Snell ; Sanjiv V. Bhave

Ascertaining an individual’s history of alcohol consumption is an important component in the proper treatment of accidental trauma or acute or chronic illness, as well as for matters of public health and safety, legal issues, insurance coverage, and the management of and recovery from hazardous/harmful levels of alcohol consumption. Although self-report of alcohol consumption in both research and clinical settings represents the most common mode of assessment, there is long-standing interest in developing objective measures of alcohol consumption that do not rely on the ability or willingness of a person to truthfully report consumption. Biologic diagnostic tests or biomarkers can provide information on current and past quantity and frequency of alcohol consumption. This chapter discusses and evaluates many of the biomarker candidates that have been investigated and provides insights into future searches for optimal diagnostic tools to provide biologic evidence of duration, quantity, and frequency of individual alcohol consumption. We have included a limited discussion of biomarkers for assessing cannabis use since cannabis and alcohol use many times are a concomitant feature of intoxication.

100 Deals associated with Lohocla Research Corp.

Login to view more data

100 Translational Medicine associated with Lohocla Research Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

2

Phase 1 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nezavist	-	Phase 1
Lohocla 201 ( NMDA receptor x Nav1.7 x Nav1.8 x δ opioid receptor )	Chronic Pain More	Phase 1
LOH-100	Nervous System Diseases More	Preclinical
mol-BCUKA	-	Discontinued